Broccoli May Boost Cancer Immunotherapy and Lower Blood Sugar
Broccoli is rarely anyone’s favorite vegetable. Its dense texture, slightly bitter taste, and lingering grassy aftertaste make it difficult for many people to enjoy. For most, the main reason to eat broccoli has always been simple: it is considered healthy.
However, emerging scientific research suggests broccoli may deserve far more attention than it typically receives. Recent studies indicate that compounds naturally found in broccoli could play a meaningful role in both cancer treatment and metabolic health.
Researchers have identified sulforaphane (SFN), a bioactive compound abundant in broccoli and other cruciferous vegetables, as a potentially powerful therapeutic adjunct. New findings suggest sulforaphane may significantly improve the efficacy of PD-1 immunotherapy in non-small cell lung cancer (NSCLC), while separate clinical research indicates it may also help reduce fasting blood glucose in certain prediabetic populations.
These discoveries are transforming broccoli from a simple “healthy vegetable” into a serious subject of biomedical interest.
🧬 Sulforaphane and Lung Cancer Immunotherapy #
Immunotherapy has become one of the most important advances in modern oncology, particularly PD-1/PD-L1 checkpoint inhibitors. Yet despite their success, a substantial percentage of patients with non-small cell lung cancer fail to respond adequately.
One of the central challenges lies within the tumor microenvironment, where immunosuppressive mechanisms weaken anti-tumor immune responses. CD8+ T cells, which are critical for destroying cancer cells, often become functionally exhausted in this environment.
Sulforaphane has long been studied for its anti-inflammatory and anti-cancer properties. Previous research demonstrated that it can:
- Modulate the tumor immune microenvironment
- Enhance CD8+ T-cell activity
- Promote apoptosis of myeloid-derived suppressor cells (MDSCs)
- Reduce immunosuppressive signaling
Researchers from Zhengzhou University investigated whether sulforaphane could enhance the effectiveness of PD-1 immunotherapy in NSCLC patients.
DOI: 10.1002/mco2.70688
From Mouse Models to Human Clinical Data #
The research began with mouse models using Lewis lung carcinoma cells. Investigators tested a combination therapy consisting of:
- Sulforaphane
- Chemotherapy
- PD-1 antibody therapy
The triple-combination regimen produced the strongest anti-tumor effects. Tumor growth was significantly suppressed, and among five long-term surviving mice, three achieved complete tumor regression.
Encouraged by these findings, the team launched a prospective clinical study involving 80 NSCLC patients. After propensity score matching, the final analysis included:
- 30 patients receiving sulforaphane + chemotherapy + PD-1 inhibitor
- 30 patients receiving chemotherapy + PD-1 inhibitor alone
The results were notable.
Clinical Outcomes #
Patients receiving sulforaphane supplementation demonstrated substantial improvements across multiple clinical endpoints:
| Clinical Metric | Sulforaphane Group | Control Group |
|---|---|---|
| Objective Response Rate (ORR) | 86.7% | 60.0% |
| Disease Control Rate (DCR) | 100% | 93.3% |
| Median Progression-Free Survival (PFS) | 19 months | 9.5 months |
The median progression-free survival nearly doubled in the sulforaphane group, suggesting a potentially meaningful enhancement of immunotherapy efficacy.
Enhanced Immune Activation #
Immune profiling revealed additional insights into the underlying mechanisms.
After sulforaphane treatment:
- Activated CD8+ T cells increased significantly
- CD69 activation markers were elevated
- Exhausted PD-1+ and CTLA-4+ CD8+ T cells decreased
- MDSCs and regulatory T cells (Tregs) were reduced
Imaging mass cytometry further showed increased infiltration of CD4+ and CD8+ T cells within tumor tissue. Cytotoxic markers such as Granzyme B and proliferation marker Ki67 were elevated in both T cells and NK cells.
At the same time, PD-L1 expression on M2 macrophages and MDSCs was suppressed.
Evidence of Strong Immune Responses #
Two patients in the experimental group developed new pulmonary lesions during treatment. Biopsies later confirmed these lesions were not true tumor progression, but rather inflammatory necrosis caused by massive immune-cell infiltration — a phenomenon known as pseudoprogression.
After continuing the same treatment regimen, the lesions subsequently shrank or nearly disappeared.
These observations further support the hypothesis that sulforaphane may amplify anti-tumor immune responses.
The researchers concluded that sulforaphane could serve as a promising immunosensitizer for NSCLC treatment.
🩺 Broccoli and Blood Sugar Regulation #
Broccoli’s therapeutic potential may extend beyond oncology.
Researchers from the University of Gothenburg recently published a randomized controlled clinical trial in Nature Microbiology examining whether broccoli sprout extract rich in sulforaphane could improve glucose metabolism in prediabetic individuals.
DOI: 10.1038/s41564-025-01932-w
Participants consumed broccoli sprout extract daily for 12 weeks.
The study found that fasting blood glucose levels declined by an average of 0.2 mmol/L compared with placebo. Although the reduction did not meet the study’s predefined primary endpoint of 0.3 mmol/L, the intervention demonstrated a favorable safety profile with only mild gastrointestinal discomfort reported.
Personalized Response Patterns #
One of the study’s most important findings was that sulforaphane’s effectiveness appeared highly individualized.
Researchers identified that participants classified under the Mild Age-Related Diabetes (MARD) subtype experienced the strongest benefits:
| Diabetes Subtype | Fasting Glucose Reduction | Insulin Function | Overall Response |
|---|---|---|---|
| MARD (Mild Age-Related) | 0.4 mmol/L | Improved | Strong |
| SIRD (Severe Insulin-Resistant) | Minimal | No major change | Weak |
| MOD (Mild Obesity-Related) | Minimal | No major change | Weak |
This suggests that broccoli-derived interventions may not produce uniform metabolic benefits across all prediabetic populations.
The Role of Gut Microbiota #
The researchers also discovered that gut microbiota composition strongly influenced treatment outcomes.
Individuals with higher abundance of the Bacteroides BT2160 operon were able to convert inactive broccoli-derived compounds into active sulforaphane more efficiently. Higher circulating sulforaphane levels correlated with improved blood sugar control.
Additionally:
- Responders tended to harbor more butyrate-producing bacteria
- Non-responders exhibited microbiota enriched with oral pathogens
- Non-responders also showed elevated liver-fat-related markers
This research represents one of the first clinical demonstrations that gut microbial functional genes may directly influence the metabolic efficacy of dietary phytonutrients.
The findings could pave the way for more personalized nutrition strategies targeting prediabetes and metabolic disorders.
🥦 Why These Findings Matter #
The growing body of research surrounding broccoli and sulforaphane highlights an important shift in nutritional science: certain dietary compounds may exert clinically meaningful biological effects beyond basic nutrition.
Current evidence suggests sulforaphane may:
- Enhance anti-tumor immune responses
- Improve immunotherapy efficacy
- Reduce immunosuppressive signaling
- Support glucose regulation in specific populations
- Interact closely with gut microbiota and metabolic health
At the same time, these studies should be interpreted carefully. Broccoli is not a replacement for cancer therapy or diabetes treatment, and the findings remain part of an evolving research landscape requiring larger clinical validation.
Nevertheless, the data reinforce the value of cruciferous vegetables as part of a health-conscious diet.
What was once dismissed as an ordinary green vegetable is increasingly attracting attention as a scientifically significant functional food.